- Conditions
- Multiple Myeloma
- Interventions
- All-Trans Retinoic Acid (ATRA) Dose 0, All-Trans Retinoic Acid (ATRA) Dose 1
- Drug
- Lead sponsor
- The Methodist Hospital Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 1
- States / cities
- Houston, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1441–1464
of 5,767
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Leukemia
- Interventions
- cytarabine, idarubicin, pravastatin
- Drug
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005
- U.S. locations
- 2
- States / cities
- Houston, Texas • Seattle, Washington
- Conditions
- Lymphoblastic Leukemia, Acute, Childhood, Myelogenous Leukemia, Acute, Childhood, Hodgkin's Disease, Non-Hodgkin's Lymphoma
- Interventions
- Panobinostat, Cytarabine
- Drug
- Lead sponsor
- Therapeutic Advances in Childhood Leukemia Consortium
- Other
- Eligibility
- 8 Years to 21 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2011
- U.S. locations
- 20
- States / cities
- Los Angeles, California • San Francisco, California • Washington D.C., District of Columbia + 16 more
- Conditions
- Tumors, Brain Tumors, Rhabdomyosarcoma, Sarcoma, Soft Tissue
- Interventions
- Everolimus
- Drug
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- 3 Years to 21 Years
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2008
- U.S. locations
- 1
- States / cities
- Memphis, Tennessee
- Conditions
- Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia
- Interventions
- AUTO1
- Biological
- Lead sponsor
- Autolus Limited
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 153 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2029
- U.S. locations
- 23
- States / cities
- Duarte, California • La Jolla, California • Sacramento, California + 20 more
- Conditions
- Leukemia, Lymphoma
- Interventions
- therapeutic allogeneic lymphocytes, cyclophosphamide, cyclosporine, fludarabine phosphate, methotrexate, mycophenolate mofetil, tacrolimus, peripheral blood stem cell transplantation, radiation therapy
- Biological · Drug · Procedure + 1 more
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2003
- U.S. locations
- 19
- States / cities
- Denver, Colorado • Newark, Delaware • Orlando, Florida + 15 more
- Conditions
- MYELODYSPLASTIC SYNDROME; MDS, ACUTE MYELOID LEUKEMIA; AML
- Interventions
- Humanized anti-CD117 Monoclonal Antibody (JSP191)
- Biological
- Lead sponsor
- Jasper Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 6
- States / cities
- Duarte, California • Stanford, California • Chicago, Illinois + 3 more
- Conditions
- B-Cell Chronic Lymphocytic Leukemia
- Interventions
- bafetinib
- Drug
- Lead sponsor
- CytRx
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 2
- States / cities
- Duarte, California • Houston, Texas
- Conditions
- Anaplastic Large Cell Lymphoma, Recurrent Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma
- Interventions
- Laboratory Biomarker Analysis, Romidepsin, Venetoclax
- Other · Drug
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 2
- States / cities
- Duarte, California • Omaha, Nebraska
- Conditions
- Non Small Cell Lung Cancer Metastatic
- Interventions
- Acasunlimab, Pembrolizumab
- Biological
- Lead sponsor
- Genmab
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 125 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 6
- States / cities
- Santa Rosa, California • Fort Myers, Florida • St. Petersburg, Florida + 3 more
- Conditions
- Recurrent Adult Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
- Interventions
- Cytarabine, Filgrastim, Filgrastim-sndz, Fludarabine Phosphate, Laboratory Biomarker Analysis, Membrane-bound Interleukin-21-Expanded Haploidentical Natural Killer Cells
- Drug · Biological · Other
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2021
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Lymphoma
- Interventions
- CUDC-427
- Drug
- Lead sponsor
- Curis, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 2
- States / cities
- Nashville, Tennessee • San Antonio, Texas
- Conditions
- Small Cell Lung Carcinoma
- Interventions
- coformulation pembrolizumab/quavonlimab, lenvatinib, MK-4830, coformulation favezelimab/pembrolizumab, R-DXd
- Biological · Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 110 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2029
- U.S. locations
- 12
- States / cities
- Gilbert, Arizona • Atlanta, Georgia • Fort Wayne, Indiana + 7 more
- Conditions
- GIST
- Interventions
- BIIB021
- Drug
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 3
- States / cities
- Encinitas, California • Santa Monica, California • San Antonio, Texas
- Conditions
- Neoplasms
- Interventions
- paclitaxel
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- Not listed
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1994 – 2000
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Lymphoma
- Interventions
- filgrastim, monoclonal antibody Lym-1, cyclosporine, paclitaxel, peripheral blood stem cell transplantation, indium In 111 monoclonal antibody Lym-1, yttrium Y 90 monoclonal antibody Lym-1
- Biological · Drug · Procedure + 1 more
- Lead sponsor
- University of California, Davis
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2001
- U.S. locations
- 1
- States / cities
- Sacramento, California
- Conditions
- Refractory Brain Tumors
- Interventions
- Antineoplaston therapy (Atengenal + Astugenal)
- Drug
- Lead sponsor
- Burzynski Research Institute
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1996 – 2012
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Pain, Intractable, Pain Cancer, Pain
- Interventions
- Resiniferatoxin, Placebo
- Drug
- Lead sponsor
- Sorrento Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 4
- States / cities
- La Jolla, California • Gainesville, Florida • Portland, Oregon + 1 more
- Conditions
- AIDS-Related Kaposi Sarcoma, HIV Infection, Recurrent Kaposi Sarcoma
- Interventions
- Bortezomib, Laboratory Biomarker Analysis, Questionnaire Administration
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2015
- U.S. locations
- 9
- States / cities
- La Jolla, California • Los Angeles, California • San Diego, California + 4 more
- Conditions
- Recurrent Hodgkin Lymphoma, Refractory Hodgkin Lymphoma
- Interventions
- Basiliximab, Carmustine, Cytarabine, Etoposide, Genetically Engineered Hematopoietic Stem Progenitor Cells, Recombinant Granulocyte Colony-Stimulating Factor, Yttrium Y 90 Basiliximab
- Biological · Drug
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2029
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- Recurrent Acute Myeloid Leukemia, Recurrent Chronic Myelomonocytic Leukemia, Recurrent Myelodysplastic/Myeloproliferative Neoplasm, Refractory Acute Myeloid Leukemia, Refractory Chronic Myelomonocytic Leukemia, Refractory Myelodysplastic/Myeloproliferative Neoplasm
- Interventions
- Azacitidine, Gilteritinib, Venetoclax
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 97 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2028
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Cancer, Melanoma, Solid Tumor, Squamous Cell Carcinoma of Head and Neck, Breast Cancer, Advanced Solid Tumor, Triple Negative Breast Cancer, Colorectal Carcinoma, Non-melanoma Skin Cancer, Liver Metastases
- Interventions
- ONCR-177, pembrolizumab
- Biological
- Lead sponsor
- Oncorus, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 10
- States / cities
- Duarte, California • Denver, Colorado • Tampa, Florida + 6 more
- Conditions
- Leukaemia, Myelocytic, Acute
- Interventions
- GSK2879552, ATRA
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 5
- States / cities
- Augusta, Georgia • New York, New York • The Bronx, New York + 1 more
- Conditions
- Advanced Rare Malignant Solid Neoplasm, Rare Malignant Solid Neoplasm, Refractory Rare Malignant Solid Neoplasm
- Interventions
- Atezolizumab, Biopsy Procedure, Biospecimen Collection, Computed Tomography, Echocardiography Test, Tiragolumab
- Biological · Procedure · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 3
- States / cities
- Bethesda, Maryland • Columbus, Ohio